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Introduction
In recent years, tetanus has become a disease rarely seen in
daily clinical practice owing mainly to widespread vacci-
nation and deliveries in clean medical facility environ-
ments. However, the mortality rate is still unacceptably
high, 20–30% even with the advanced intensive care now
available. In addition, physical and psychological sequelae
may often be inevitable in tetanus survivors. In Japan, with
its aging population, tetanus tends to occur more frequently
in older people who were born before the introduction of
vaccination against tetanus. Elderly people are susceptible
to trauma due to falls or trafﬁc accidents, which can result
in the development of tetanus. On the other hand, tetanus is
a preventable disease. Educating the elderly as well as
young people about the importance of vaccination is
essential in our aging society.
Deﬁnition
Tetanus is a toxic disease caused by Clostridium tetani
neurotoxin produced in the wound. The cardinal signs of
this disease are hypertonicity and spasms of skeletal mus-
cles associated with impaired neural transmission.
Epidemiology
Currently, tetanus occurs in about 1,000,000 people annu-
ally worldwide, and most patients are newborns in devel-
oping countries located in tropical areas. The World Health
Organization (WHO) estimated that there were 715,000
deaths from tetanus among newborns in 1990.
In 1950 in Japan, the reported number of tetanus patients
was 1,915, and the number of deaths was 1,558 (81% of all
patients; the majority were children under 15 years of age).
However, since introduction of the combined diphtheria–
pertussis–tetanus (DPT) vaccine in 1968, the numbers of
patients and deaths have decreased steadily [1]. Over the
1991–2000 decade, the annual reported numbers of patients
and deaths were 50 and 14 (28%), respectively, on average.
In relation to age, those born before introduction of the
DPT vaccine in 1968 accounted for 95% of all patients.
The occurrence of tetanus is particularly frequent from
early summer to autumn, coinciding with increased outdoor
activities in older men. The disease occurs nationwide in a
virtually uniform fashion, involving slightly more men.
Trauma is regarded as a major trigger in about 80% of
cases. Since the 1980s, the reported number of patients has
been leveling off or showing a slight tendency to increase,
whereas the number of deaths has been decreasing steadily.
Tetanus was ofﬁcially added to the list of target diseases of
the routine vaccination program in April 1995 in Japan.
Etiology
C. tetani is an obligately anaerobic gram-positive rod that
forms a terminal spore, resulting in a ‘‘drumstick-like’’ or
‘‘tennis racket-like’’ appearance. The organisms occur
worldwide in soil. Spores are found in dust and soil, par-
ticularly densely in surface soil of the garden, agricultural
ﬁelds, and shorefronts of ponds or rivers [2]. C. tetani can
also be isolated from feces of animals and humans.
Vegetative C. tetani produces two exotoxins, i.e., the
neurotoxin tetanospasmin and the hemolytic toxin tetano-
lysin. Tetanospasmin is referred to as tetanus toxin,
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because it can cause tetanus. Spores of C. tetani germinate
under anaerobic conditions (decreased redox potential),
such as in the presence of necrotic tissues or foreign bodies,
and develop into vegetative cells to produce tetanus toxin.
This toxin is synthesized as a polypeptide within bacterial
cells under plasmid control, and released by autolysis of
the cells. Although humans and horses are highly suscep-
tible to the toxin, they can be immunized with tetanus
toxoid. The low incidence of tetanus, relative to the fre-
quent opportunities for contamination through trauma, may
be explained by the fact that C. tetani requires strictly
anaerobic conditions for its proliferation.
Tetanus toxin is highly potent; a lethal dose is estimated
to be 2.5 ng/kg body weight (1 g of toxin corresponds to
the lethal dose for 6,000,000 adults weighing 60 kg). Thus,
the amount of toxin required for development of tetanus is
not enough to stimulate the immune system, making toxoid
injections necessary for active immunization.
C. tetani is susceptible in vitro to b-lactams [penicillins,
particularly benzylpenicillin (penicillin G) (PCG), cep-
hems, carbapenems], macrolides, tetracycline (TC) and
metronidazole, but is resistant to aminoglycosides. Vege-
tative cells are susceptible to heat and the commonly used
disinfectants. Although glutaraldehyde is most active
against spores, it is not applicable to humans. To kill
spores, boiling at 100C for at least 4 h or autoclaving at
121C for 12 min is required.
Contributing factors
The presence of necrotic tissues, abscess or foreign bodies
provides an anaerobic environment suitable for germina-
tion of C. tetani spores. In such a wound C. tetani begins to
proliferate about 6 h after contamination with its spores.
Tetanus often results from wound contamination with soil,
dust, feces or saliva. Wood or bamboo chips, soil or
sand remaining in the wound are also dangerous. In addi-
tion, attention needs to be paid to tooth extraction, gas-
trointestinal or hemorrhoid surgery, artiﬁcial abortion, drug
abuse (use of unclean syringes), chronic eczema, chronic
otitis media, tinea pedis, cleaning of the navel, decubitus
ulcers, gangrenous lesions (e.g., diabetes mellitus and
arteriosclerosis obliterans), and dental abscess. Spore
contamination of the umbilical stump may trigger neonatal
tetanus.
Although it is difﬁcult to exclude the possibility of tet-
anus development from the appearance of a wound, risk is
relatively small for a shallow, clean cut made by a new
knife or razor. However, it has been reported that a minor
wound which the patient did not remember resulted in
tetanus. In general, wounds associated with a high risk of
developing tetanus are those with a long course from injury
to initiation of treatment, severe contamination, the pres-
ence of necrotic tissues or foreign bodies, and deep injury
(Table 1) [3].
Pathogenesis
Toxin released in the wound is taken up from the motor
nerve ending, and ascends along the axon in a retrograde
fashion to the a-motor neuron of the ventral horns of the
spinal cord, and reaches the synaptic clefts. Then, the toxin
is transmitted to presynaptic and postsynaptic inhibitory
neurons (presynaptic inhibitory neurons in the brainstem
and postsynaptic inhibitory interneurons in the spinal cord),
and blocks the release of inhibitory neurotransmitters from
these neurons [c-aminobutyric acid (GABA) and glycine,
respectively]. Thus, presynaptic excitatory neurons become
predominant, and the frequency of the resting impulse
discharges from a-motor neurons is increased (continuous
discharges of the motor units), causing muscular hyperto-
nicity, which progresses to tonic spasms (Fig. 1) [4].
Although transmitter release at the excitatory amino acid
synapse is also inhibited, afﬁnity of the toxin for the
inhibitory synapse surpasses such inhibition, resulting in
enhanced muscular hypertonicity. On the other hand, ace-
tylcholine release from the motor nerve ending at the
neuromuscular junction is also inhibited. This may cause
Table 1 Clinical characteristics
of tetanus-prone wounds
(modiﬁed from Ref. [3])
Clinical characteristics Tetanus-prone wounds Non-tetanus-prone wounds
Time after injury [6 h B6 h
External features of wound Irregular wound, laceration, abrasion Linear wound
Depth of wound [1 cm B1 cm
Mechanism of injury Bullet wound, crush injury, burn, frostbite Sharp surface (knife, glass)
Signs of infection Present Absent
Necrotic tissue Present Absent
Contaminants (dust, feces,
soil, saliva)
Present Absent
Denervated/ischemic tissue Present Absent
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ﬂaccid paralysis, but the effect of the toxin on the central
nervous system (CNS) is the major clinical picture of the
disease. In severe tetanus, there is accompanying disinhi-
bition of preganglionic sympathetic neurons present in the
lateral grey matter of the spinal cord, leading to sympa-
thetic hyperactivity and increased blood levels of cate-
cholamines. The neural afﬁnity of tetanus toxin is so strong
that binding of the toxin is irreversible. Therefore, recovery
from tetanus requires generation of new axon terminals.
Tetanus toxin spreads to local and distant nerve end-
ings through direct diffusion into neighboring muscles,
lymphogenic or hematogenic carriage, and retrograde
intra-axonal transport. However, the toxin does not pass
the blood–brain barrier. Assuming that the velocity of
intra-axonal transport (75–250 mm/day) is equal among
different nerves, short nerves should be affected earlier
than long nerves. This explains why nerves in the head
are affected ﬁrst, followed by those of the trunk and
extremities.
Since C. tetani itself does not cause inﬂammation, the
responsible wound may look clean as long as there is no
infection with other bacteria.
Vaccination against tetanus (active immunization)
For prevention of tetanus as well as diphtheria and per-
tussis, the DPT vaccine was introduced as part of a vac-
cination program in infants in 1968. Since 1995, DPT
vaccination comprising 3 initial doses and 1 booster dose
(phase I) and DT vaccination (1 dose) (phase II) have been
performed as part of the routine vaccination program.
Therefore, adults currently age 41 years or older, i.e., those
born before 1968, probably do not have antibody (anti-
toxin) against tetanus toxin. Vaccination against tetanus is
carried out in Japan, as shown in Table 2 [5]. Although
tetanus can affect anyone, at any time or place, vaccination
is particularly recommended for people who are more
likely to suffer trauma with a risk of exposure to C. tetani.
Such people include those engaged in civil engineering and
construction, stock farming, agriculture or landscaping,
police ofﬁcers, ﬁreﬁghters, self-defense ofﬁcials, house-
wives, and those aged 60 years or older.
Individuals can achieve basic immunity to tetanus after
at least 3 doses of tetanus toxoid (a primary series).
Thereafter, 1 booster dose is given every 10 years and may
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Fig. 1 Mechanism of action of tetanospasmin (tetanus toxin). a Retrograde intra-axonal transport, b blockade of inhibitory synapse (modiﬁed
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be required every 5–10 years, taking into account the
occupation of the vaccinated person.
In order to prevent neonatal tetanus, unvaccinated preg-
nant women should be given 2 doses of adsorbed tetanus
toxoid (0.5 mL) at an interval of at least 4 weeks after
5 months of gestation, and a third dose 3 months later (e.g.,
vaccine inoculations at 20, 24 and 36 weeks of gestation) [5].
The WHO’s Expanded Programme on Immunization rec-
ommends that 2 doses be given at an interval of 4 weeks or
more, and that the second dose be scheduled at least 2 weeks
before delivery. There are virtually no vaccine side effects
when vaccination is performed according to this schedule.
Clinical symptoms
There are four clinical types of tetanus: generalized,
cephalic, neonatal and localized. These clinical types
reﬂect differences in host immunity against tetanus, the
portal of entry, and the primary site of toxin action. Gen-
eralized tetanus accounts for 85–90% of reported cases.
The incubation period and the ‘‘onset period’’ are used for
evaluating the severity of tetanus in the initial stage and its
prognosis (Table 3) [6]. The incubation period refers to the
time between injury (spore inoculation) and the develop-
ment of the initial symptom (in most cases difﬁculty in
opening the mouth, or trismus), and the ‘‘onset period’’
refers to the time between trismus development and the
ﬁrst generalized spasms.
Generalized tetanus
The incubation period is usually 7–10 days (range
2–30 days), and depends largely on the distance between
the wound site and the CNS. In severe cases, the incubation
period is usually within 7–9 days, and the onset period
Table 2 Current vaccination against tetanus (modiﬁed from Ref. [5])
1. Routine vaccination
Phase I 4 doses with DPT vaccinea in infants 3 months or older, within 90 months after birth
Initial vaccination: basically, 3 doses at 3- to 8-week intervals in infants 3 months or older and not more than 12 months after birth
Booster vaccination: basically, 1 dose 12-18 months after completion of initial vaccination regimen
Phase II 1 dose of DT toxoidb in children 11 years of age or older but younger than 13 years; basically, sixth graders (12-year-old children)
2. Basic immunity in people not vaccinated against tetanus (spontaneous vaccination)
Initial vaccination: 2 doses of adsorbed tetanus toxoid at a 4- to 8-week interval
Booster vaccination: basically, 1 dose of adsorbed tetanus toxoid 6–18 months after completion of the initial vaccination regimen
3. Booster vaccination in people who are more than 13 years old and have not received phase II vaccination and those in whom 10–15 years have
elapsed since the last dose (spontaneous vaccination)
One dose of adsorbed tetanus toxoid
a Adsorbed diphtheria-puriﬁed pertussis–tetanus combined vaccine
b Adsorbed diphtheria–tetanus combined toxoid
Table 3 Rating scale for the severity and prognosis of tetanus (modiﬁed from Ref. [6])
1. Rating items: 1 point for each applicable item
(1) Incubation period\7 days
(2) ‘‘Onset period’’\48 h
(3) Burns, surgical wound, compound fracture, septic abortion
(4) Narcotic addiction
(5) Generalized tetanus
(6) Fever[40C
(7) Tachycardia[120 beats/min ([150 beats/min in neonates)
2. Severity and prognosis
Total score Severity Mortality (%)
0–1 Mild \10
2–3 Moderate 10–20
4 Severe 20–40
5–6 Serious [50
Cephalic tetanus should be rated as severe or serious, and neonatal tetanus as serious
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within 48 h. Trismus or ‘‘lockjaw’’ reﬂects hypertonicity
and spasms of the masseter muscles, being found as the
initial symptom in 75% of patients. This is because the
masseter muscles are innervated by the trigeminal nerve,
which is characterized by the shortest course from the
neuromuscular nerve endings to the motor nucleus. The
patient becomes irritable and restless, and presents per-
spiration, difﬁculty swallowing, salivation, and stiffness
and pain of the muscles of the neck, shoulder and back.
Persistent trismus progresses into risus sardonicus due to
sustained contraction of the facial muscles. Development
of tonic spasms of the back muscles causes opisthotonus
characterized by backward arching of the head, neck and
spine, similar to decorticate rigidity. At this time, upper
limbs are ﬂexed and adducted, with the ﬁsts clenched
tightly on the chest, and the lower limbs extended. Severe
painful generalized spasms may involve respiratory mus-
cles and the glottis. Thus, cyanosis or even suffocation due
to hypoventilation and apnea is not uncommon. Muscle
spasms not only repeat spontaneously but are also easily
induced by minor sensory stimuli such as sound, cold air
and touch. Fever may be noted in some cases, but most
patients are afebrile. Throughout the course of the illness,
the patient maintains clear consciousness.
In severe cases, concurrent autonomic dysfunction,
particularly sympathetic hyperactivity, appears within
several days after the onset. The patient presents sustained
or labile hypertension, tachycardia, arrhythmias, high
fever, marked diaphoresis, peripheral vasoconstriction,
urinary retention, or increased catecholamine levels in the
blood and urine. Cardiac arrest occurs occasionally. Para-
sympathetic hyperactivity is rare.
Even if antitoxin is administered, the disease progresses
for about 2 weeks, the time interval required for transport
of the toxin that has already entered the axon. This is
because antitoxin can neutralize toxin not yet bound to the
neural tissues. An additional month is required for
recovery.
Complications include spasm-related bone fractures
(particularly vertebrae and long bones), deep venous throm-
bosis, pulmonary thromboembolism, bacterial infections
(e.g., aspiration pneumonia), decubitus ulcers, dehydration,
rhabdomyolysis, rupture of muscles, and intramuscular
hematomas.
Localized tetanus
This type of tetanus is characterized by muscle spasms in
the limb associated with a contaminated wound. Symptom
severity varies widely among patients, from simple muscle
weakness (due to disturbed neuromuscular transmission) to
severe painful muscle spasms progressing to generalized
disease. The condition is considered to reﬂect partial
immunity to tetanus. Muscle spasms may persist for several
weeks to several months, but the prognosis is favorable as
long as the muscle involvement is localized.
Cephalic tetanus
This type is a special form of localized tetanus. Usually, the
disease is secondary to trauma involving the head or face,
or results from contamination with C. tetani spores in
chronic otitis media. The incubation period is only
1–2 days. Characteristic clinical symptoms include trismus
and isolated or combined cranial motor nerve palsies, with
conspicuous muscle weakness in areas innervated by the
seventh (facial) nerves. Extraocular muscles may also be
involved. The condition may remain localized, or progress
into generalized tetanus.
Neonatal tetanus
This type of tetanus arises from unclean procedures for
treating the umbilical stump in neonates mostly in devel-
oping countries. In general, the disease onset is 3–10 days
after birth (incubation period). Based on the average
incubation period, this disease is called ‘‘the disease of the
seventh day.’’ The affected neonate initially presents gen-
eral debility, poor sucking and irritability, followed by
generalized tonic spasms. The primary causes of death
among neonates 1 and 2 weeks after birth are apnea and
sepsis (primary focus: bacterial infection of the umbilical
stump), respectively. The mortality rate exceeds 90%, and
growth retardation is noted in survivors. The antepartum
immune status of the mother, particularly lack of vacci-
nation, is key to the development of neonatal tetanus.
Diagnosis
A clinical diagnosis of tetanus is made based on the
characteristic symptoms, i.e., hypertonicity and spasms of
skeletal muscles. In general, microbiologic examinations,
consisting of isolation of C. tetani from the wound and
toxin production, are not performed, because the organism
is rarely isolated from the wound and because occasionally
any wound cannot be found. In addition, tetanus will not
necessarily occur even if the characteristic spore-forming
organisms are observed by microscopic examination of
smear preparations, or if C. tetani is isolated by culture.
Tetanus should be suspected and the patient’s course
followed carefully when subtle prodromal symptoms have
occurred after an injury (stiffness of muscles around the
wound, jaw or neck, and equivocal complaints such as a
general feeling of illness). If muscular hypertonicity with
associated generalized spasms are more prominent in the
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central part of the body (face, neck, chest, back and
abdomen) than in the extremities, tetanus should be
strongly suspected.
It is important to investigate the history of vaccination
against tetanus. Tetanus is quite unlikely if the serum
antitoxin level is equal to or higher than the commonly
cited protective concentration of 0.10 IU/mL (or 0.15 IU/mL),
although there have been some reports of exceptional
cases [5, 7].
Leukocytosis, particularly neutrophilia, occurs, but there
are generally no abnormal cerebrospinal ﬂuid ﬁndings. The
levels of muscle-derived enzymes, such as serum creatine
kinase, are increased. Electroencephalographic studies
generally show a sleep pattern, and the electromyogram
exhibits continuous motor unit discharges and shortening
of the non-discharge period following the action potential.
However, these ﬁndings are not sufﬁciently speciﬁc to
establish a diagnosis.
Tetanus is designated by what is called the Infectious
Diseases Control Law as an infectious disease of Type V,
a group subject to complete-count survey. Therefore, if
tetanus is suspected, the physician in charge is legally
required to report the case to a local healthcare center near
by within 7 days of diagnosis.
Differential diagnoses include strychnine poisoning,
dystonic reactions or oculogyric crisis due to phenothiazine
or metoclopramide toxicity, meningitis/encephalitis, epi-
leptic seizures, subarachnoid hemorrhage, dental abscess,
tetany due to hypocalcemia or alkalosis, alcohol with-
drawal syndrome, rabies, and acute abdomen (due to
abdominal guarding). Although strychnine poisoning par-
ticularly resembles tetanus, patients with the former disease
show muscle spasms not accompanied by hypertonicity and
have high blood and urine strychnine levels, allowing
differentiation from tetanus. Strychnine antagonizes gly-
cine at the inhibitory synapse. Dystonic reactions also
resembles tetanus, but responds to anticholinergic drugs
unlike tetanus and can thereby be distinguished from
tetanus.
Therapeutic management
Primary treatment goals
Treatment of tetanus is roughly divided into wound and
general management. Wound management consists of (1)
removal of the source of toxin by deterging or debridement
of the wound, (2) neutralization of unbound toxin by
antitoxin (passive immunization), and (3) control of
infection with antibacterial therapy. General management
requires (1) control of muscle spasms using sedative and
antispasmodic agents or muscle relaxants, (2) respiratory
care with artiﬁcial ventilation, (3) treatment of auto-
nomic dysfunction, particularly sympathetic hyperactivity
(administration of ab-blockers or ganglion blockers), and
(4) supportive care (nutritional support with nasal feeding
or parenteral nutrition, prevention and treatment of decu-
bitus ulcers and deep venous thrombosis, vaccination to
prevent further attacks, mental and psychological support).
Therefore, it is recommended that patients with suspected
or diagnosed tetanus be transferred to medical facilities
having a critical care center or ICU.
Antibacterial agents
PCG (10,000,000–12,000,000 units/day, in 4 divided doses,
i.v., for 10 days) is generally administered to kill vegeta-
tive cells, the source of toxin. In Europe and the US,
however, metronidazole (500 mg per dose, 4 times a day,
per os or i.v., for 7–10 days: this treatment is not covered
by health insurance in Japan) tends to be preferred. In this
regard, it is known that PCG serves as a GABA antagonist
[8]. When there is contamination with soil or feces,
appropriate antibacterial agents should be used with sus-
picion of mixed infection with other bacteria [for example,
PIPC 4 g/day, in 4 divided doses; or cefazolin (CEZ) or
cefmetazole (CMZ) 3–4 g/day, in 3–4 divided doses].
Deterging or debridement of the wound and removal of
foreign bodies are necessary for successful antibacterial
therapy.
Administration of antitoxin (passive immunization)
Critical prevention immediately after injury
Antitoxin [human tetanus immunoglobulin (TIG)] neu-
tralizes circulating toxin in the blood (and some in the
wound as well) before it can bind to the neural tissues. The
risk of developing tetanus should be estimated from the
condition of the wound (Table 1), and 250 IU of TIG for
prophylaxis should be given intramuscularly or intrave-
nously as soon after the injury as possible. For severe
trauma cases, 1,500 IU should be given intravenously.
Repeated administration is necessary for extensive second-
degree burns. It is recommended that TIG be administered
prior to providing debridement or opening of the wound.
The serum antitoxin titer is maintained above 0.01 IU/mL,
the lower limit of the protective level range [minimum
protective level (MPL)] within 4 weeks after intramuscular
or intravenous injection of 250 IU (covering almost the
entire incubation period of tetanus). The peak blood level
of antitoxin is attained about 2 days after intramuscular
injection.
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Therapeutic administration after onset
In order to shorten the course after the onset or to alleviate
symptoms of tetanus, TIG should be administered prior to
providing debridement or opening of the wound. At least
5,000 IU, administered intramuscularly (usually in divided
doses because of the large quantity), or 1,500–3,000 IU for
mild to moderate cases and 3,000–4,500 IU for severe
cases, administered intravenously, should be used, with
increasing doses according to the disease state. The optimal
doses have not been established, and intramuscular injec-
tion of 500 IU reportedly achieves an efﬁcacy comparable
to that of higher doses. The biological half-life of TIG in
the blood is 3–4 weeks after intravenous or intramuscular
administration. There are no established criteria for
choosing intravenous or intramuscular TIG. The route
presumably most appropriate for the individual patient
should be chosen.
Toxoid administration (active immunization)
Vaccination immediately after injury
Vaccination immediately after injury is not necessary if
the patient has completed a primary 3-dose series and it
has not been more than 5 years since the last dose
(Table 4) [9]. Those who have completed a primary series
and in whom more than 5–10 years have elapsed since
the last dose should receive a booster dose if at risk of
developing tetanus. Prompt acquisition of a high serum
antitoxin titer can be expected from this dose (booster
effect). Non-immunized or partially immunized individu-
als who have received\3 doses should immediately aim
to complete the 3-dose series. Patients with an unknown
history of vaccination (including those who were born
before introduction of the DPT vaccine in 1968) should
be dealt with as non-immunized individuals in case of
emergency.
Vaccination during convalescence
Recovery from tetanus does not confer immunity. Con-
sidering the risk of sustaining a similar injury, it is nec-
essary to complete a primary vaccination series to avoid
recurrent tetanus. Therefore, active immunization by
means of adsorbed tetanus toxoid should be initiated during
the recovery period. It is desirable that the unvaccinated
patient be given 2 doses during hospitalization and dis-
charged with a ﬁxed schedule for the third dose. When TIG
is given intramuscularly, the toxoid should be inoculated at
a distant site from the injection site, e.g., by a contralateral
subcutaneous or intramuscular route.
Control of muscle spasms
Benzodiazepines (diazepam or midazolam) are often used to
control muscle spasms and produce sedation. In particular,
diazepam, which exerts a GABA-ergic effect, is the drug of
choice, and is administered with a dose escalation of 5 mg
increments according to the symptoms. When tonic spasms
subside, doses of benzodiazepines should be reduced over at
least 2 weeks to avoid withdrawal reaction. However, it is
often difﬁcult to obtain sufﬁcient control of muscle spasms
even with high doses of diazepam, necessitating combined
use of a sedative (propofol), antispasmodic (baclofen) or
muscle relaxant (vecuronium or dantrolene).
Since even minor sensory stimuli induce spasms, a
darkened, quiet environment is optimal.
Respiratory care
The airway and ventilatory function should be evaluated
immediately after the ﬁrst examination. In severe cases,
artiﬁcial ventilation (maintenance of adequate ventilation)
should be initiated after endotracheal intubation (protection
of the airway), because there is a risk of respiratory failure
or suffocation due to excessive sedation or spasms of the
Table 4 Prevention of tetanus in wound management (modiﬁed from Ref. [9])
History of vaccination against tetanus
(adsorbed tetanus toxoid)
Clean, minor wound All other woundsa
Toxoidb TIG Toxoidb TIG
Unknown or\3 doses Necessary Unnecessary Necessary Necessary
C3 doses Unnecessaryc Unnecessary Unnecessaryd Unnecessary
a Including, but not limited to, wounds contaminated with dust, feces, soil or saliva (deep punctures and lacerations), bullet wounds, crush
injuries, burns and frostbite
b DPT vaccine (or DT toxoid) is used for children younger than 7 years of age. DT toxoid is used for those 7 years or older
c Vaccine should be given if more than 10 years have elapsed since the last dose
d Vaccine should be given if more than 5 years have elapsed since the last dose
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glottis or respiratory muscles. If endotracheal intubation
induces spasms, tracheostomy is indicated. It is recom-
mended that nasogastric intubation be carried out at the
same time as endotracheal intubation.
Control of autonomic dysfunction
Autonomic dysfunction results from excessive catechol-
amine release associated with sympathetic hyperactivity.
To control blood pressure, the ab-blocker labetalol is
usually used. In treating hypertension, infusion of mor-
phine on magnesium sulfate, and epidural blockade of the
renal plexus may also be performed. In hypotensive cases,
infusion of dopamine or noradrenalin is used in addition to
ﬂuid therapy. The use of a pacemaker may be necessary to
treat bradycardia.
Prognosis
The mortality rate from generalized tetanus is 20–30%
even with current advanced respiratory and circulatory
management in an ICU (the mortality rate is about 10% in
mild to moderate cases, but reaches up to 60% in severe
cases). The cause of death is most frequently pneumonia,
but autopsy reveals no signiﬁcant ﬁndings in some cases.
Such cases probably represent deaths due to autonomic
dysfunction, particularly cardiovascular complications,
attributable to the neurotoxicity of tetanus toxin. Neonates
and elderly patients have a poor prognosis. The prognosis
is also poor in patients with a short incubation period or
‘‘onset period’’ and in those with a short interval between
the clinical manifestation (trismus) and admission. In
general, the prognosis is inﬂuenced by the history of
vaccination.
Patients usually recover in 4–6 weeks even when they
have the generalized form of moderate or severe disease.
During this period, patients usually need intensive care
with ventilatory support. Patients may suffer from muscu-
lar hypertonicity or minor spasms over several months, but
the premorbid condition is usually restored. Neuromuscular
transmission disorder of lower motor neurons may become
apparent after spasms have resolved, and recovery from
this disorder requires several weeks. The seriousness of
tetanus (pain and dyspnea due to severe tonic spasms under
clear consciousness) and its treatment (prolonged ICU
management using artiﬁcial ventilation) can produce per-
sistent psychic trauma long after recovery from the disease,
and psychotherapy may be required.
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